Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
Becton Dickinson and Company (BDX), a global medical technology provider focused on diagnostic tools, medication delivery systems, and laboratory equipment, is trading at $155.23 as of 2026-04-06, marking a 0.47% gain in the most recent trading session. This analysis outlines key technical levels, broader market context, and potential near-term scenarios for the stock, with no recent earnings data available to inform fundamental performance assessments at this time. Key takeaways include a neutr
Is BD (BDX) Stock Near Support | Price at $155.23, Up 0.47% - Gamma Alerts
BDX - Stock Analysis
3508 Comments
625 Likes
1
Marquel
Elite Member
2 hours ago
This feels oddly specific yet completely random.
👍 246
Reply
2
Joymarie
Community Member
5 hours ago
I feel like I just agreed to something.
👍 205
Reply
3
Tyrhonda
Regular Reader
1 day ago
Short-term volatility is noticeable, but the overall market trend remains intact for patient investors.
👍 236
Reply
4
Maui
Insight Reader
1 day ago
Could’ve done something earlier…
👍 173
Reply
5
Vaino
New Visitor
2 days ago
This feels illegal but I can’t explain why.
👍 267
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.